| Literature DB >> 11123362 |
L Beni-Adani1, I Gozes, Y Cohen, Y Assaf, R A Steingart, D E Brenneman, O Eizenberg, V Trembolver, E Shohami.
Abstract
Brain injury induces disruption of the blood-brain barrier, edema, and release of autodestructive factors that produce delayed neuronal damage. NAPSVIPQ (NAP), a femtomolar-acting peptide, is shown to be neuroprotective in a mouse model of closed head injury. NAP injection after injury reduced mortality and facilitated neurobehavioral recovery (P < 0.005). Edema was reduced by 70% in the NAP-treated mice (P < 0.01). Furthermore, in vivo magnetic resonance imaging demonstrated significant brain-tissue recovery in the NAP-treated animals. NAP treatment decreased tumor necrosis factor-alpha levels in the injured brain and was shown to protect pheochromocytoma (PC12 cells) against tumor necrosis factor-alpha-induced toxicity. Thus, NAP provides significant amelioration from the complex array of injuries elicited by head trauma.Entities:
Mesh：
Substances：
Year: 2001 PMID： 11123362
Source DB: PubMed Journal: J Pharmacol Exp Ther ISSN： 0022-3565 Impact factor: 4.030